Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sul- famethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice

Authors: Antunes F, Cardoso F, Cushion MT, Esteves F, Lobo ML, Matos O
Journal: PLoS One
Link: http://www.ncbi.nlm.nih.gov/pubmed/23940606

Pneumocystis pneumonia (PcP) is a major cause of mortality and morbidity in immunocompromised patients. There are limited alternative therapeutic choices to trimethoprim-sulfamethoxazole (TMP-SMX) which is the standard first line therapy/prophylaxis for PcP.
Read More

Pneumocystis jirovecii multilocus genotyping in pooled DNA samples: a new approach for clinical and epidemiological studies.

Authors: Antunes F, Esteves F, Gaspar J, Mansinho K, Matos O
Journal: Clinical Microbiology and Infection
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Pneumocystis+jirovecii+multilocus+genotyping+in+pooled+DNA+samples%3A+a+new+approach+for+clinical+and+epidemiological+studies.

Specific single-nucleotide polymorphisms (SNPs) are recognized as important DNA sequence variations influencing the pathogenesis of Pneumocystis jirovecii and the clinical outcome of Pneumocystis pneumonia, which is a major worldwide cause of illness among immunocompromised patients
Read More

Population structure of Pneumocystis jirovecii isolated from immunodeficiency virus-positive patients

Authors: Antunes F, Esteves F, Gaspar J, Mansinho K, Matos O, Moser I, Tavares A
Journal: Infection Genetics and Evolution
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Population+structure+of+Pneumocystis+jirovecii+isolated+from+immunodeficiency+virus+positive+patients

Pneumocystis jirovecii pneumonia (PcP) is an important opportunistic infection among immunocompromised patients. Genetic characterization of P. jirovecii isolated from HIV-positive patients, based on identification of multiple nucleotide sequences at eight distinct loci, was achieved by using PCR with DNA sequencing and RFLP.
Read More

Identification of relevant single-nucleotide polymorphisms in Pneumocystis jirovecii: relationship with clinical data

Authors: Antunes F, Esteves F, Gaspar J, Leite R, Mansinho K, Marques T, Matos O
Journal: Clinical Microbiology and Infection
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Identification+of+relevant+Single+Nucleotide+Polymorphisms+in+Pneumocystis+jirovecii%3A+relationship+with+clinical+data

Pneumocystis jirovecii is a poorly understood pathogen that causes opportunistic pneumonia (Pneumocystis pneumonia (PcP)) in patients with AIDS.
Read More

Baseline susceptibility of primary HIV-2 to entry inhibitors.

Authors: Antunes F, Barroso H, Bártolo I, Borrego P, Caixas U, Calado R, Cavaco-Silva P, Doroana M, Maltez F, Marcelino JM, Rocha C, Taveira N
Journal: Antiviral Therapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Baseline+susceptibility+of+primary+HIV-2+to+entry+inhibitors

BACKGROUND:
The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown.
Read More

Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sul- famethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice

Pneumocystis jirovecii multilocus genotyping in pooled DNA samples: a new approach for clinical and epidemiological studies.

Population structure of Pneumocystis jirovecii isolated from immunodeficiency virus-positive patients

Identification of relevant single-nucleotide polymorphisms in Pneumocystis jirovecii: relationship with clinical data

Baseline susceptibility of primary HIV-2 to entry inhibitors.

About GHTM

Contacts

Subscribe Newsletter